[Back to Our Trials]
PACIFIC-4: Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
Condition: Non-small Cell Lung Cancer
Go To Trial Homepage
For more information you may call clinical trials department directly at 732-390-7750 or email us at
astera.clinicaltrial@asterahealthcare.org
.